Advances in cohort enrichment shape future of trial design
Author:
Publisher
Springer Science and Business Media LLC
Subject
Rheumatology
Link
http://www.nature.com/articles/nrrheum.2014.222.pdf
Reference10 articles.
1. Cobo-Ibáñez, T. et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. http://dx.doi.org/10.1016/j.semarthrit.2014.04.002 .
2. Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 6, 498–506 (2011).
3. van Laar, J. M. et al. EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 25, 2490–2498 (2014).
4. Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum. 66, 1625–1635 (2014).
5. Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51, 1017–1026 (2012).
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Current Status and Future Direction of Extracellular Nano-vesicles in the Alleviation of Skin Disorders;Current Stem Cell Research & Therapy;2024-04
2. Tenascin-C in fibrosis in multiple organs: Translational implications;Seminars in Cell & Developmental Biology;2022-08
3. New mechanism-based approaches to treating and evaluating the vasculopathy of scleroderma;Current Opinion in Rheumatology;2021-08-16
4. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial;Annals of the Rheumatic Diseases;2020-04-15
5. Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials;The Lancet Rheumatology;2020-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3